在重症监护中推进剂量兰地的血液动力学和节律学影响-一项回顾性横截面研究
Sebastian Schnaubelt1, Felix Eibensteiner1, Julia Oppenauer1
1Department of Emergency Medicine, Medical University of Vienna, 1090 Vienna, Austria.
Pharmaceuticals (Basel, Switzerland)
|June 1, 2023
概括
推进剂量兰迪洛尔在危急病患者中有效控制了心率,没有显著的血压变化. 这项研究发现,在重症监护病房中,玻尿酸囊配方安全有效地控制了脑上脉上高心率.
科学领域:
- 关键护理医学 关键护理医学
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 兰地醇是一种β1选择性β-阻断剂,有效控制心律不变的持续心率.
- 有限的数据存在于 bolus 配方在重症患者的疗效和安全性.
研究的目的:
- 评估推进剂量兰迪洛尔在重症患者中对脑膜上下心跳动的疗效和安全性.
- 为了评估血动力学和呼吸系统效应的玻尿酸兰地洛尔的管理.
主要方法:
- 追溯性横截面研究重症监护患者的突然发病的脑膜上下心动减速症治疗的推进剂量兰迪洛洛.
- 通过侵入性血压监测收集的连续血液动力学数据.
主要成果:
- 41%的应用实现了心率控制; 27%实现了节律控制.
- 服用后观察到显著的心率下降 (145到105bpm,p<0.001).
- 血压或呼吸系统设置 (FiO2) 没有临床显著的变化. 没有报告严重不良事件.
结论:
- 推进剂量兰迪阿洛尔在重症监护病房患者中证明了安全性和有效性.
- 没有观察到临床上对血压的相关影响,以大剂量兰迪洛洛.
相关概念视频
Heart Failure Drugs: Inotropic Agents
644
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
644
Cardiopulmonary Resuscitation IV: Pharmacological Management
30
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
30
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
784
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
784
Heart Failure Drugs: β-Blockers
394
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
394
Adrenergic Antagonists: ɑ and β-Receptor Blockers
527
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
527
Heart Failure III: Clinical Manifestations
28
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
28


